Helen is focused on pre clinical development for therapeutic areas at Life Edit Therapeutics. She has over a decade of experience in in vivo animal modeling of human disease pathology and treatment.
Prior to joining Life Edit, Helen was a Postdoctoral Fellow at UNC-Chapel Hill where she utilized genetically modified rodent models to develop AAV-based CRISPR-Cas9 gene therapy in treating Angelman Syndrome.
Helen received her PhD in Molecular Genetics and Microbiology from Duke University, where she studied post-transcriptional regulation and its role in embryonic brain development.
.svg)
.svg)
To rewrite the future by curing disease, making any edit, anywhere.
To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.
We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.
